EP4367140A4 - Anti-tnfr2-antikörper und verwendungen davon - Google Patents

Anti-tnfr2-antikörper und verwendungen davon

Info

Publication number: EP4367140A4
Authority: EP; European Patent Office
Prior art keywords: tnfr2 antibody; tnfr2; antibody
Prior art date: 2021-07-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP22837100.1A

Other languages

English (en)

French (fr)

Other versions

EP4367140A1 (de

Inventor

Nicola Arturo Aldo BELTRAMINELLI

Jennifer Watkins

Francisco Adrian

Qian Zhang

Andreas Raue

Pascaline Mary

Liang SCHWEIZER

Shuo WEI

Matthieu DELINCE

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

HiFiBiO Inc

Original Assignee

HiFiBiO Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-07-07

Filing date

2022-07-06

Publication date

2025-06-18

2022-07-06 Application filed by HiFiBiO Inc filed Critical HiFiBiO Inc

2024-05-15 Publication of EP4367140A1 publication Critical patent/EP4367140A1/de

2025-06-18 Publication of EP4367140A4 publication Critical patent/EP4367140A4/de

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP22837100.1A 2021-07-07 2022-07-06 Anti-tnfr2-antikörper und verwendungen davon Withdrawn EP4367140A4 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US202163219175P	2021-07-07	2021-07-07
PCT/IB2022/000409 WO2023281313A1 (en)	2021-07-07	2022-07-06	Anti-tnfr2 antibody and uses thereof

Publications (2)

Publication Number	Publication Date
EP4367140A1 EP4367140A1 (de)	2024-05-15
EP4367140A4 true EP4367140A4 (de)	2025-06-18

Family

ID=84800439

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP22837100.1A Withdrawn EP4367140A4 (de)	2021-07-07	2022-07-06	Anti-tnfr2-antikörper und verwendungen davon

Country Status (9)

Country	Link
EP (1)	EP4367140A4 (de)
JP (1)	JP2024527576A (de)
KR (1)	KR20240032985A (de)
CN (1)	CN117980336A (de)
AR (1)	AR126387A1 (de)
AU (1)	AU2022308421A1 (de)
CA (1)	CA3224693A1 (de)
TW (1)	TW202309096A (de)
WO (1)	WO2023281313A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL316894A (en) *	2022-05-26	2025-01-01	Pfizer	ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF
WO2024233258A1 (en) *	2023-05-05	2024-11-14	Cureimmune Therapeutics Inc.	Anti-tnfr2 antibodies and uses thereof
WO2026119935A1 (en)	2024-12-03	2026-06-11	Resano Gmbh	Combination comprising a tumor necrosis factor receptor 2 agonist
WO2026119926A1 (en)	2024-12-03	2026-06-11	Resano Gmbh	Agonist polypeptide for use in treating and/or preventing heart failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2020061210A1 (en) *	2018-09-18	2020-03-26	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017040312A1 (en) *	2015-08-28	2017-03-09	The General Hospital Corporation	Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2019094559A2 (en) *	2017-11-09	2019-05-16	The General Hospital Corporation	Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
CN113874083A (zh) *	2019-03-01	2021-12-31	梅里麦克制药股份有限公司	抗-tnfr2抗体及其用途
EP3907240A4 (de) *	2019-08-02	2023-02-22	Jiangsu Simcere Pharmaceutical Co., Ltd.	Anti-tnfr2-antikörper und verwendung davon
AU2020348224A1 (en) *	2019-09-17	2022-05-12	Apexigen, Inc.	Anti-TNFR2 antibodies and methods of use
CN112480259B (zh) *	2021-02-05	2021-05-04	百奥赛图(北京)医药科技股份有限公司	抗tnfr2抗体及其用途

2022
- 2022-07-06 JP JP2024500409A patent/JP2024527576A/ja active Pending
- 2022-07-06 AU AU2022308421A patent/AU2022308421A1/en active Pending
- 2022-07-06 CA CA3224693A patent/CA3224693A1/en active Pending
- 2022-07-06 EP EP22837100.1A patent/EP4367140A4/de not_active Withdrawn
- 2022-07-06 WO PCT/IB2022/000409 patent/WO2023281313A1/en not_active Ceased
- 2022-07-06 AR ARP220101767A patent/AR126387A1/es unknown
- 2022-07-06 TW TW111125395A patent/TW202309096A/zh unknown
- 2022-07-06 KR KR1020247004535A patent/KR20240032985A/ko active Pending
- 2022-07-06 CN CN202280060055.4A patent/CN117980336A/zh active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2020061210A1 (en) *	2018-09-18	2020-03-26	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2023281313A1 *
WEI SHUO ET AL: "DiscoveryandcharacterizationofnovelTNFR2antibodiestomodulateTcellactivities inimmunosuppressiveenvironment", AACR, vol. 80, 3 July 2020 (2020-07-03), pages 2282 - 2282, XP055913355, Retrieved from the Internet <URL:http://hifibio.com/wp-content/uploads/2020/07/Poster-2282-AACR-2020-conference-poster_TNFR2.pdf> [retrieved on 20250508], DOI: https://doi.org/10.1158/1538-7445.AM2020-2282 *

Also Published As

Publication number	Publication date
WO2023281313A1 (en)	2023-01-12
CN117980336A (zh)	2024-05-03
EP4367140A1 (de)	2024-05-15
KR20240032985A (ko)	2024-03-12
TW202309096A (zh)	2023-03-01
AU2022308421A1 (en)	2024-01-25
AR126387A1 (es)	2023-10-11
JP2024527576A (ja)	2024-07-25
CA3224693A1 (en)	2023-01-12

Legal Events

Date	Code	Title	Description
2023-01-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2024-04-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2024-04-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2024-05-15	17P	Request for examination filed	Effective date: 20240129
2024-05-15	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-06-26	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: HIFIBIO, INC.
2024-10-16	DAV	Request for validation of the european patent (deleted)
2024-10-16	DAX	Request for extension of the european patent (deleted)
2025-06-18	A4	Supplementary search report drawn up and despatched	Effective date: 20250520
2025-06-18	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/39 20060101ALI20250514BHEP Ipc: A61P 35/00 20060101ALI20250514BHEP Ipc: C12N 15/13 20060101ALI20250514BHEP Ipc: A61K 39/00 20060101ALI20250514BHEP Ipc: C07K 16/28 20060101AFI20250514BHEP
2026-04-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2026-05-06	18D	Application deemed to be withdrawn	Effective date: 20251209

Publication	Publication Date	Title
EP3838289A4 (de)	2022-08-03	Anti-tigit-antikörper und verwendungen davon
EP3958910A4 (de)	2023-08-02	Anti-cd45-antikörper-wirkstoff-konjugate und verwendungen davon
EP4388009A4 (de)	2025-07-09	Anti-ccr8-antikörper und verwendungen davon
EP3918323A4 (de)	2022-12-28	Anti-gal3-antikörper und verwendungen davon
EP4269435A4 (de)	2025-06-18	Anti-b7-h3-antikörper und verwendungen davon
EP3762030A4 (de)	2022-01-05	Anti-cd73-antikörper und verwendungen davon
EP3759143A4 (de)	2022-03-02	Anti-tigit-antikörper und verwendungen davon
EP4100439A4 (de)	2024-05-29	Neuartige lilrb2-antikörper und verwendungen davon
EP4132974A4 (de)	2024-05-08	Anti-cd98-antikörper und verwendungen davon
EP4136116A4 (de)	2024-06-19	Anti-ox40-antikörper und verwendungen davon
EP4261223A4 (de)	2024-11-13	Anti-sirp? antikörper und anwendung davon
EP4281107A4 (de)	2025-03-12	Anti-kit-antikörper und verwendungen davon
EP3962954A4 (de)	2023-01-18	Anti-galectin-9-antikörper und verwendungen davon
EP3790586A4 (de)	2022-01-19	Anti-dll3-antikörper und verwendungen davon
MA52190A (fr)	2021-02-17	Anticorps anti-trem-1 et utilisations associées
EP4010368A4 (de)	2023-09-06	Anti-nampt-antikörper und verwendungen davon
EP3850012A4 (de)	2022-06-15	Anti-tnfrsf9-antikörper und verwendungen davon
EP3947462A4 (de)	2023-01-11	Anti-galectin-9-antikörper und verwendungen davon
EP3755714A4 (de)	2022-02-16	Anti-angiopoietin-2-antikörper und verwendungen davon
EP4081548A4 (de)	2024-07-24	Anti-sirp? monoklonale antikörper und verwendung davon
EP3907240A4 (de)	2023-02-22	Anti-tnfr2-antikörper und verwendung davon
EP3768317A4 (de)	2021-12-22	Anti-il-27-antikörper und verwendungen davon
EP3938389A4 (de)	2022-11-09	Tsg-6-antikörper und verwendungen davon
EP4326777A4 (de)	2024-09-04	Humanisierte anti-sialyl-tn-glycanantikörper und verwendungen davon
EP3829606A4 (de)	2022-07-06	Anti-cd79-antikörper und deren verwendungen